臨床前 CRO 市場規模、佔有率、成長分析（按服務、按型號、按應用、按最終用戶、按地區）- 產業預測 2025-2032

預計 2023 年全球臨床前 CRO 市場規模將達到 64 億美元，並從 2024 年的 70.1 億美元成長到 2032 年的 146 億美元，預測期內（2025-2032 年）的複合年成長率為 9.6%。

全球臨床前合約組織 (CRO) 市場的成長主要得益於生物製藥公司、醫療設備公司和政府研究機構日益成長的參與度，這些公司以合約方式利用 CRO 服務。慢性病和基因相關疾病的快速成長要求這些公司投入大量資金進行研究，以開發用於有效診斷和治療的創新藥物和設備。臨床前 CRO 透過提供必要的研發解決方案，簡化藥物和設備開發流程，使這些公司能夠專注於其核心業務。此外，對新型救命療法的迫切需求也推動了對臨床前研究的投資，鞏固了 CRO 在藥物開發和商業化策略中的關鍵作用。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

臨床前 CRO 市場規模（依服務及複合年成長率） (2025-2032)

• 市場概覽
• 生物分析和 DMPK 研究
  • 試管內ADME
  • 體內藥物動力學
• 毒性測試
  • GLP
  • 非GLP
• 化合物管理
  • 製程研究與開發
  • 客製合成
  • 其他
• 化學
  • 藥物化學
  • 計算化學
• 安全藥理學
• 其他

臨床前 CRO 市場規模（依型號及複合年成長率） (2025-2032)

• 市場概覽
• 患者來源的類器官（PDO）模型
• 患者來源的異種移植模型

臨床前 CRO 市場規模：按應用和複合年成長率（2025-2032）

• 市場概覽
• 腫瘤學
• 神經病學
• 心臟病學
• 感染疾病
• 代謝紊亂
• 其他

臨床前 CRO 市場規模（依最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 製藥和生物技術公司
• 政府和學術機構
• 醫療設備公司
• 其他

臨床前 CRO 市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Charles River Laboratories International, Inc.（USA）
• Labcorp Drug Development（USA）
• Eurofins Scientific（Luxembourg）
• ICON plc（Ireland）
• IQVIA（USA）
• Parexel International Corporation（USA）
• PPD（USA）
• Syneos Health（USA）
• Crown Bioscience（USA）
• Envigo（USA）
• Intertek Group plc（UK）
• SGS SA（Switzerland）
• MPI Research（USA）
• Worldwide Clinical Trials（USA）
• Inotiv, Inc.（USA）
• Jubilant Biosys Ltd.（India）

結論和建議

Global Preclinical CRO Market size was valued at USD 6.4 billion in 2023 and is poised to grow from USD 7.01 billion in 2024 to USD 14.6 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The growth of the global preclinical contract research organization (CRO) market is significantly fueled by the increasing engagement of biopharmaceutical companies, medical device firms, and government research agencies, who leverage CRO services on a contractual basis. The surge in chronic and gene-related diseases necessitates substantial investment from these companies in research aimed at the development of innovative drugs and devices for effective diagnosis and treatment. Preclinical CROs enable these organizations to concentrate on core activities by providing essential research and development solutions, thereby streamlining the drug and device creation process. Additionally, the urgent demand for new life-saving therapies is propelling investments in preclinical research, solidifying the crucial role of CROs in drug development and commercialization strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preclinical CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preclinical CRO Market Segments Analysis

Global Preclinical CRO Market is segmented by Service, Model, Application, End User and region. Based on Service, the market is segmented into Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology and Others. Based on Model, the market is segmented into Patient-Derived Organoid (PDO) Model and Patient-Derived Xenograft Model. Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical and Biotechnological Companies, Government and Academic Institutes, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Preclinical CRO Market

A significant catalyst for the growth of the global preclinical Contract Research Organization (CRO) market is the swift expansion of the biopharmaceutical industry. As biopharmaceutical companies increasingly venture into the development of innovative drugs, they are turning to CROs to manage essential preclinical testing activities, including drug efficacy evaluations and toxicity assessments. This growing reliance on outsourcing preclinical research functions not only enhances efficiency but also allows biopharma firms to focus on their core competencies. Consequently, the demand for preclinical CRO services is anticipated to rise substantially in the future, driven by this ongoing trend in the industry.

Restraints in the Global Preclinical CRO Market

One significant restraint in the Global Preclinical CRO market is the potential loss of management control during the development process when outsourcing preclinical testing. Biopharmaceutical companies that engage third-party CROs may find themselves with diminished oversight of their research activities. This dependency can hinder progress, as it may lead to delays, miscommunication, and inconsistent results. Consequently, a lack of direct management can restrict innovation and efficiency, ultimately affecting the overall success of drug development projects. These challenges underline the importance of careful selection and communication when collaborating with contract research organizations.

Market Trends of the Global Preclinical CRO Market

The Global Preclinical Contract Research Organization (CRO) market is experiencing a significant trend toward the integration of automation and artificial intelligence (AI), revolutionizing research operations. This transformation facilitates faster and more accurate outcomes, allowing for optimized data processing and predictive modeling in drug development. As AI-driven solutions become widespread, they not only enhance efficiency but also significantly reduce time and costs associated with preclinical studies. This trend underscores a broader shift within the industry towards embracing cutting-edge technologies, indicating that the market is poised for continued growth and innovation as organizations increasingly leverage these advancements to streamline their operations and improve research productivity.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Preclinical CRO Market Size by Service & CAGR (2025-2032)

• Market Overview
• Bioanalysis and DMPK studies
  • In vitro ADME
  • In-vivo PK
• Toxicology Testing
  • GLP
  • Non-GLP
• Compound Management
  • Process R&D
  • Custom Synthesis
  • Others
• Chemistry
  • Medicinal Chemistry
  • Computation Chemistry
• Safety Pharmacology
• Others

Global Preclinical CRO Market Size by Model & CAGR (2025-2032)

• Market Overview
• Patient-Derived Organoid (PDO) Model
• Patient-Derived Xenograft Model

Global Preclinical CRO Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Metabolic Disorders
• Others

Global Preclinical CRO Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical and Biotechnological Companies
• Government and Academic Institutes
• Medical Device Companies
• Others

Global Preclinical CRO Market Size & CAGR (2025-2032)

• North America (Service, Model, Application, End User)
  • US
  • Canada
• Europe (Service, Model, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Model, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Model, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Model, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Envigo (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intertek Group plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MPI Research (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Worldwide Clinical Trials (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotiv, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Biosys Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations